AZN Stock Recent News
AZN LATEST HEADLINES
The Dow Jones Industrial Average (DJIA) is one of the oldest and most widely recognized stock market indices in the world.
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Polaris Pharmacy Services, a leading provider of long-term care and specialty pharmacy solutions, has been selected as the exclusive U.S. distributor for FluMist® Home, AstraZeneca's at-home flu vaccine service available for the 2025-2026 flu season. Through FluMist Home, individuals can order FluMist online to be delivered directly to their home on a date they choose—no doctor's visit or needle required. The program is the first of its kind to receive FD.
AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.
The HBA's ACE Awards spotlight bold, people-first programs that are transforming how the industry develops, engages, and empowers its workforce. FAIRFIELD, N.J.
AstraZeneca PLC boasts strong 2024 results with $54B revenue and 14 blockbuster drugs, driven by robust growth in oncology and rare disease franchises. Key products like Farxiga, Tagrisso, and Ultomiris show impressive growth, but looming patent expiries and legal risks threaten future revenues. Heavy R&D investment and strategic moves into cell/gene therapy and AI-driven drug discovery support AstraZeneca's long-term growth outlook.
Thursday is ex-dividend day in London and this week there was a heavyweight billing that knocked the FTSE 100 sideways, including companies such as AstraZeneca PLC (LSE:AZN), NatWest Group PLC (LSE:NWG) and Rolls-Royce Holdings PLC (LSE:RR.). There were 18.3 points collectively shaved off the index as a result of 12 blue-chips going ex-dividend on the day, when investors who purchase shares today are no longer entitled to their latest dividend payouts.
BOSTON and ROLLE, Switzerland , Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies for certain types of breast cancer.
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
JNJ edges out AZN following Q2 results with raised guidance, stronger estimate revisions and a more attractive valuation.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.